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Abstract In 2003 the Cleveland Clinic Brain Tumor
Institute sponsored a symposium to mark the progress
being made in what was then a new approach to
treating brain tumors—convection enhanced delivery
(CED) [Vogelbaum MA (2005) J NeuroOncol
73(1):57–69]. A second symposium was held in Feb-
ruary, 2006, to review new accomplishments and
identify promising avenues of research in this evolving
but still novel therapy. Among the general subjects
covered by a host of international experts in their
respective fields were advances in CED technology,
new clinical applications of the technology, advances in
CED-related imaging procedures, reviews of current or
proposed trials, new drugs and the status of projects
moving from lab to clinical practice. Specific subjects
included the design of new catheters, the development
of mathematic models for planning, novel therapeutics
for CED treatment of stroke, spinal cord degenerative
disease and epilepsy, liposome-based agents adminis-
tered via CED, ultra-sound driven CED, monitoring
the in vivo effects of intratumoral paclitaxel and other
topics. Each speaker’s presentation has been
abstracted along with relevant references.
Keywords Blood–brain barrier  Brain tumor 
Convection enhanced delivery  Gliomas  Targeted
therapy
Introduction
Three years ago, in 2003, the Cleveland Clinic Brain
Tumor Institute convened a symposium to describe the
state of what was then the relatively new concept of
convection enhanced delivery (CED) [1]. We con-
vened a second symposium on CED in February, 2006,
to mark three years of progress and chart a path into
the future. The technology, although still in its infancy,
retains its promise. The international panel of investi-
gators who attended this year’s meeting in Cleveland
discussed new technologies, refinements of existing
technologies, the development of new mathematic
models that will allow therapies to be designed to meet
specific clinical presentations in specific patients,
refinements in imaging to allow more accurate real-
time imaging of therapeutic infusions and monitor the
progress of therapies, and development of new thera-
peutic agents amenable to CED treatment of brain
tumors. In short, most every aspect of this developing
field was discussed in detail. The following are sum-
maries of the presentations.
Novel catheters for CED I
Krys Bankiewicz M.D., Ph.D. (Associate Professor of
Neurological Surgery, University of California, San
Francisco) began his remarks by describing a host of
variables that affect the distribution of an agent within
a targeted area of the brain. Among these are the
character of the agent, the character of the therapy
(acute or chronic), the location of the cannula, the
nature of target tissue, and the physical properties of
the cannula itself (i.e. its size, shape and the shape and
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number of openings at the end of the cannula or
needle.) A final aspect of understanding these prop-
erties is developing imaging technology that will allow
the dispersal of agents to be understood and thus better
controlled.
One of the initial considerations is the diameter of
the infusion cannula, which appears to have a signif-
icant affect on reflux. In this instance, reflux is not the
agent moving back into the bore but the tendency of
an injected agent to move back along the outer sur-
face of the shaft between the shaft and tissue it has
penetrated. It first coats the shaft and then disperses
into surrounding tissue but at a different rate than it
does from the tip of the cannula. The movement of an
agent back along the shaft of can be rapid. There
appears to be a critical size for cannula of around 26
gauge. Studies in agarose gels show that smaller
cannulas perform better than larger and convect fluid
at a greater rate.
A ‘‘step design cannula’’ consists of sequence of ever
smaller shafts, each terminating at a different point
along the device with the smallest at the distal end. The
concept is to move an infusate from various points
along the shaft at a constant rate to create a reasonably
balanced dispersion pattern. One such cannula, now in
gene therapy trials, is composed of four layers of 304
surgical steel fused by laser welding to a step design,
ending in 23 gauge tubing. The steel cannula is lined
with fused silica, which also forms the tip that extends
1 cm beyond the steel. The device has been dubbed by
some as a ‘‘reflex resistant cannula.’’
There appears to be a yet to be described pumping
mechanism or transport mechanism in the perivascular
space that moves molecules within tissue. Magnetic
resonance imaging (MRI) of liposomes injected into
brain tissue shows them being distributed by this
mechanism. The phenomena is being studied further.
Novel catheters for CED II
Michael Bronskill, Ph.D. (Department of Medical
Biophysics, University of Toronto) asked attendees to
think of CED technology not as a collection of
instruments but as therapy delivery system whose
configuration can be altered according to clinical cir-
cumstance. Such a system may involve varied types of
cannulas, a pump, connecting tubes, flow monitors and
imaging technology. The success of therapy depends on
placing the agent on target and that the agent being
administered assumes a volume and shape that maxi-
mizes its effect. Time is a consideration with some
agents.
Successful infusion requires that the chosen
cannula is inserted into the target tissue in such a
manner that the agent perfusing from the instrument’s
multiple orifices assumes a predetermined volume and
shape within a given amount of time. Clinical
circumstances may dictate single infusions, multiple
infusions, intermittent or continuous infusion. All
these approaches require an accurate imaging tech-
nology that allows the perfused agent’s shape to be
monitored in real time.
Early work with multi-port catheters show they are
somewhat prone to flow anomalies. It is possible that
this problem can be overcome with better designs. Air
entrapped in the cannula can create severe problems
with uniform drug distribution and is to be avoided at
all costs.
A theme that runs through a number of experiments
with cannulas of different designs is that smaller bore
cannulas are more likely to create good flow patterns
and good pressure profiles. As cannulas get larger and/
or more complicated backflow and the shape of the
volume of infusion become difficult to impossible to
control.
Mathematical models of CED
Paul Morrison, Ph.D. (Division of Bioengineering and
Physical Science, National Institutes of Health) pro-
posed that the technology of CED is at a point where
drug distribution in the central nervous system can be
predicted with a certain degree of confidence. Among
the major factors that influence CED are convective
and diffusive fluxes, intracellular space (ICS) and
extracellular space (ECS) partitioning, microvascular
transport, extra-choroidal fluid production, metabo-
lism, endocytosis and proelastic expansion.
He described mathematical means of translating
physiologic-biochemical factors into equations that al-
low the construction of mathematical models that will
produce a description of the distribution of parent
metabolite concentrations in space and time in tissue.
The underlying mathematical factors in these models
rest on known parameters such as time-dependent
conservation of mass and momentum relationships
involving tissue fluids and solids and the infusate.
Empirical data on the pharmacodynamics of varied
agents can be incorporated to produce equations
whose solutions can influence clinical decisions.
An example of this is an equation developed several
years ago [2] that determines how far back along a
catheter a fluid will move when dispersed under spe-
cific pressure from a catheter’s tip. The pressure that
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forces the fluid from the tip of the cannula has a dual
effects. It drives the fluid through the interstices in the
tissue and also acts on the tissue as a whole pushing it
away from the cannula to create a narrow annular
space through which infusate flows toward the distal
section of the instrument.
These equations that have been developed allow
diffusion patterns to be pre-determined. For example,
gemcitabine is a small molecule with a molecular
weight of 266. A model of gemcitabine infused into
gray matter at 3 ul/min through a 28-gauge needle
shows the perfused compound to assume a tear-drop
shape that gradually evolves to a more spherical shape.
Mathematical models of large volume infusions have to
take into account the distribution of irregular geometry
as the infusate is transported across white-gray
boundaries. Since white matter is involved, fiber-
directed flow has to be accounted for.
One of the therapeutic approaches being considered
today is the infusion of a substance P receptor (SPR)
directed neurotoxin into the spinal cord to reduce
chronic neuropathic pain [3, 4]. Early work involved
injecting the drug into the intrathecal space. However,
a better, more physiological model involves placing a
catheter into the dorsal column and using the spinal
cord white matter tracts as a drug reservoir that allows
the agent to move toward targeted lamina. As antici-
pated, the drug showed a preference to flow parallel to
white fiber. This finding demonstrates that a compu-
tational model of the system has to take into account
white matter anisotropy.
These and other experiments have helped the cre-
ation of formulas that govern white and gray matter
diffusion, white and gray matter hydraulics and cellular
porosity. The latter formula helps determine the
amount of active agent actually entering the cytosol.
One of the larger problems in creating mathematical
models of drug delivery is defining metabolic parame-
ters within the cytosol. If errors in estimating final
responses are to creep into the formula, they are most
likely to derive from the range of interacting metabolic
factors affecting the concentration of the active drug.
The mathematical models developed from animal
studies have helped create models of human spinal
cord infusion of substance P-diphtheria toxin (SP-DT).
This toxin targets neurokinin type 1 (NK1) receptor
expressing neurons [4]. By plugging a range of infusate
concentrations into this particular model, the authors
were able to identify the optimal concentration of the
therapeutic. The framework of this model allows other
drugs and tracer agents to incorporated into the for-
mula, again to determine which concentrations are
likely to produce optimal results.
The work is far from complete. Study continues on
white matter anisotropy. It must be remembered that
these models are proceeding in three dimensions, four
if time is considered to be a factor.
Computational modeling of CED
Raghu Raghavan, Ph.D. (Therataxis, Baltimore,
Maryland) said that the drawbacks to early mathematic
models of infusate patterns is that they were built
around finite parameters. These models were infor-
mative but the clinical value of a mathematical model
that accurately predicts patterns lies in its ability to
be tailored to individual clinical circumstances.
Dr. Raghavan and his colleagues are working with the
above described NIH model of backflow to develop
software that will allow for patient-specific planning of
CED therapy.
It is known that the length of backflow or reflux is
dependent on fluid viscosity, flow rate, the hydraulic
resistance of the tissue, the outer radius of the catheter
and the shear modulus or the tissues deformation by
the catheter and infusion. The backflow theory is pri-
marily a steady state theory that assumes that param-
eters such as pressure, flow rate and others reach an
equilibrium. Dr. Raghavan challenged this assumption
of equilibrium. He stipulated that the flow rate must be
maintained for a significant interval before any sem-
blance of equilibrium is reached and by the time
equilibrium is reached, simple models of diffusion such
as that used to predict backflow become suspect.
There are other factors to be considered in making a
more robust model. Pressure forces water into the
capillaries. The loss of this fluid increases the concen-
tration of the agent. Eventually, the agent itself will
move into the capillaries or will become metabolized.
This also alters concentrations.
Dr. Raghavan summarized his remarks to that point
in his presentation by saying that in order to compute
backflow, one needs to know some of the tissue prop-
erties near the catheter. In order to compute the fluid
flow in tissue, one needs to know the hydraulic con-
ductivity and efflux. In areas of blood–brain barrier
disruptions, there are interstitial variations, which fur-
ther complicate the picture.
To-date, one of the factors that has not been ade-
quately addressed is poroelasticity. In white matter,
poroelasticity can be a dominating effect and there is a
question as to whether the edema produced by infusion
alters the tissue to a degree that additional MR scan-
ning is required to insure the accuracy of the initial
predictions. Repeated scans should be unnecessary if
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the predictions are accurate and involve all variables to
include the edema.
Use of advanced MRI protocols for modeling
Martin Brady, M.D. (Therataxis, Baltimore, Maryland)
described how MRI can provide much of the data
needed to give mathematic models validity in a specific
patient. The patient-specific factors are hydraulic con-
ductivity, elastic moduli, pore fraction, and extracel-
lular diffusion.
The key to acquiring data for calculating hydraulic
conductivity and elastic moduli is diffusion tensor
imaging (DTI) which allows the observation of
molecular diffusion in tissues. A modulus of elasticity
is a mathematical representation of a structure’s ten-
dency to be deformed by the force acting upon it. In
the case of CED, the structures are the tissues of the
brain and the force is the infused agent. Data acquired
by DTI allow both the hydraulic conductivity and the
elastic moduli to be calculated.
DTI provides an overall view of diffusion and
information on extracellular diffusion; intracellular
diffusion must calculated. Information on exchange
diffusion or exchange rate does not significantly affect
the overall model because the timing of the MR
reduces its impact on the formula. The data that can be
used to create a simple, patient-specific formula are the
signals coming from the extracellular and intracellular
water. Both signals are weighted with the extracellular
diffusion being treated as standard Gaussian diffusion
and the intracellular diffusion being treated as
restricted diffusion. Treating the intracellular diffusion
as restricted diffusion reduces the size of its factor and
allows it to be used as a constant. DTI allows the
extracellular fraction to be estimated which in turn can
be used to obtain a rough estimate of the pore fraction.
These are many, but not all of the variables needed to
create a patient-specific mathematic model of the dif-
fusion. Further work is underway to refine imaging and
computational techniques, which will allow for the
development of better, patient-specific models.
CED for stroke: engineering chimeric proteins
to safeguard neurons
Although much of the discussion during the two-day
symposium focused on the destruction of tumor tissue,
Antonella Antignani, Ph.D. (National Institute of
Neurological Disorders, NIH) offered a window into
the utilization of CED to protect and preserve tissue.
The technology offers promise in preventing the
neuronal destruction resulting from stroke.
Her laboratory focuses on neuronal cell death.
Insults such as hypoxia or ischemia initiates apoptosis
in affected cells. The laboratory is working to develop
drugs that will block the apoptotic cycle and thus
preserve neurons that would otherwise be destroyed.
CED may well be the most effective means of getting
the agent to the cells threatened by an insult, which
may produce apoptosis.
Sensitivity to apoptotic stimuli is governed in large
part by the expression of proteins in the BCL-2 family,
which include both pro- and anti-apoptotic members.
There are two proteins in the BCL-2 family that are of
particular interest: BCL-2 and BCL-XL. These two
proteins are highly expressed during neuron develop-
ment prior to birth and BCL-XL, a homolog of BCL-2,
is expressed both before and after birth. Study of these
proteins in the rat brain shows they can block apoptosis
induced by ischemia [5]. Other studies show that BCL-
XL can cross cellular membranes. Dr. Antignani and
her colleagues have developed a chimeric protein using
BCL-XL and a portion anthrax cDNA that serves as an
antigen-binding domain. The resulting Lfn-BCL-XL
chimera has a molecular weight of 52 kDa.
The first in vivo evidence that the chimera inhibited
apoptosis came from animal studies in rat optic nerves
[6]. Following injury and transection, the number of
pyknotic cells decrease significantly in tissues treated
with Lfn-BCL-XL. Spinal cord injury models show that
BCL-XL is present in white and gray matter in
undamaged cells and is also expressed in neurons and
normal oligodendrocytes. The level of the protein ap-
pears to decrease following mild contusion to the
spinal cord. Continuing study shows that LFN-BCL-XL
protects both motoneurons and neurons in the deep
dorsal horn.
Dr. Antignani said the work to-date allows the fol-
lowing observations and conclusions: LFN-BCL-XL can
be transduced efficiently into neurons; a single injection
of LFN-BCL-XL into a spinal cord site will diffuse into
neighboring spinal cord segments; (50% of these
neighboring neurons will die following injury at an
adjacent site); LFN-BCL-XL will significantly increase
the number of neurons; the protein does not degrade at
24 h post injection; and, LFN-BCL-XL has the ability to
significantly increase the number of neurons 24 h after
injury. The significant sparing of dorsal horn neurons
and motoneurons after LFN-BCL-XL administration
suggests that the protein may be expected to improve
sensory and motor recovery following spinal cord
injury. Optimal outcomes may be achieved with higher
dosages or more frequent injections.
100 J Neurooncol (2007) 83:97–109
123
The ability of CED to obtain drug concentrations
higher than those seen with systemic administration of
the protein may enhance the distribution and pro-
survival effects of the agent. This makes CED-
mediated delivery of LFN-BCL-XL a promising
approach to treating spinal cord injuries and disorders
involving neuronal apoptosis.
Novel therapeutics for spinal cord degenerative
diseases
Nicholas Boulis, M.D. (Center for Neurological Res-
toration, Cleveland Clinic) opened his discussion by
observing that amyotrophic lateral sclerosis (ALS) and
spinal muscular atrophy (SMA) are diseases that are
tenable targets for CED therapies. The loss of motor
neurons in ALS inevitably leads to death, often within
five years. SMA is similar to ALS with the exception
that it strikes in childhood and can evolve rapidly or
slowly throughout the first 15–20 years of life. Multiple
sclerosis, although not the focus of this brief discussion,
is a third disease that lends itself to CED therapies. In
this latter instance, CED may be a viable means of
delivering factors that regulate the immune system and
encourage myelinization.
Therapeutic options for ALS and SMA include
replacing motor neurons and/or replacing glia, which
are thought to be the source of motor neuron toxicity.
Indeed, cells that pump therapeutic protein can be
delivered to the spinal cord one of the limitations of
such protein based therapies is their duration. Proteins
are metabolized relatively quickly. The same might be
said of growth factors being delivered for therapy.
CED may circumvent these obstacles. It offers a means
of penetrating both the parenchyma and the plasma
membrane barrier to deliver proteins and engineered
viruses into cells.
However, no known therapy can restore life to a dead
cell; the cell must be replaced. Dr. Boulis described
work elsewhere which has taken advantage of current
understanding of cell differentiation to essentially grow
motor neurons in vitro [7, 8]. These cells transplanted to
rats with destroyed motor neurons will grow axons and
dendrites and begin to synapse on muscle cells. These
growth and synapse processes can occur only if neurite
outgrowth inhibitor (Nogo) is suppressed. Glial cell line
derived neurotrophic factor (GDNF) appears to pull
the developing axons into the ventral roots. Experi-
mental animals receiving these treatments have recov-
ered a degree of motor function. CED may be an
important technology for delivering GDNF and/or
inhibitors of Nogo to the targeted repair site.
The advantages that CED offers in seeding cells to
damaged areas also apply to viruses engineered to
deliver therapeutic genes. The use of CED may allow
concentrations of these to be maintained over time.
RNA silencing allows the expression of genes and
therefore the proteins they produce to be blocked.
CED may have a role in delivering these new thera-
pies.
Dr. Boulis said that outside the clinical realm,
treating the spinal cord also presents an engineering
challenge. The cord can tolerate a range of insults such
as manipulation, the insertion of a needles and the
expansion of tissue or volume as happens when a
tumor grows. It cannot tolerate hemisection or tran-
section, repeated stress or traction, constriction, or
inflammation. These obstacles can be overcome with
mechanics. A system has been designed that immobi-
lizes the cannula to be mounted to the spine. The
cannula, supports, delivery system and entire platform
would move as a single unit to allow programmed
delivery of therapeutics.
Restorative biodelivery in neurodegenerative
disorders
Lars U. Wahlberg, M.D., Ph.D. (NsGene A/S,
Denmark) discussed some of the therapies being
described such as encapsulated cell (EC) biodelivery, a
technology whose character is somewhat similar to
CED systems.
The delivery system involves implanting a 60 mm
diameter catheter-like device into targeted areas of the
brain. The distal end of the device is a semi-permeable
membrane that allows the diffusion of molecules with
molecular weights of up to 90 kDa to move into the
surrounding tissue. Dr. Wahlberg noted the membrane
can be engineered to allow molecules of up to 300 kDa
to pass through. The implant holds cells that have been
genetically modified to produce therapeutic proteins.
The pores in the membrane are sized allow proteins to
move from the cells into the surrounding tissue and
nutrients to move into the implant to feed the cells.
However, the pores are too small to allow immune
cells to reach the modified cells. His company is
working with the Karolinska Institute to develop
therapies for Alzheimer’s disease and with Lund Uni-
versity to develop treatments for Parkinson’s disease.
Alzheimer’s disease is a diffuse neurodegenerative
disease with cholinergic degeneration affecting cho-
linergic neurons in the basal forebrain, cortex and
hippocampus. These particular disease locations are
noted because animal models of the disease suggest
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that halting degeneration in these regions retards the
symptomatic development of the disease. This cholin-
ergic system is normally supported by nerve growth
factor (NGF) but as the disease progresses, the signals
carried from the nerve endings to the cell bodies is
impaired. Delivering NGF locally to cell bodies
restores the system and permits distal functioning.
Clinical trials now being planned will involve six
patients. Three will receive bilateral EC implants
into the nucleus basalis. Cortical projections from the
nucleus basalis control attention. The second three
patients will receive bilateral EC implants and
bilateral anteriomedial implants. Anteriomedially
located cholinergic neurons project to the hippo-
campus and control learning and memory. The initial
responses will be monitored with positron emission
tomography (PET) but cognitive outcomes will also
be evaluated.
Glial cell line derived neurotrophic factor is a pro-
tein involved in the generation of striatal projections of
dopaminergic cells [9–12]. It is being studied for its
potential protective and regenerative potential in
Parkinson’s disease. Animal experiments have shown
that GDNF can offer a degree of protection to cells in
the substantia nigra that are insulted with injected
neurotoxins. Significant regeneration of TH-positive
nerve endings of dopaminergic cells has been observed
in animal models [13]. It appears that the encapsulated
GDNF can regenerate striatal neurons.
In vivo imaging of CED—human studies
John Sampson, M.D., Ph.D. (Duke University Medical
Center) described early attempts to obtain single
photon emission computed tomography (SPECT) and
MRI images of CED diffusion patterns with the use of
radiolabeled albumin. These images were among the
first to offer some idea of convection induced move-
ment of agents in the brain and they produced some
surprises. Among the initial findings was the discovery
that CED produced large and fairly homogenous dis-
tributions of infusate. However, significant portions of
the brain remained uninfused. One of the surprising
and perhaps disappointing findings was that in a
majority of the infusions, the drug did not enter the
brain. Of 16 infusions imaged in eight patients, seven
(44%) of the infusions showed a partial subarachnoid
leak. Two (12%) of the infusions showed a partial
ventricular leak. There was a partial pooling of the
agent in a resection of the necrotic area in four (26%)
of the infusions. Only three (19%) of the infusions
could be considered a success.
The images showed that whenever the pia was per-
forated by the tip of the catheter, there was no infusion
into the parenchyma. Catheter tips that approached
the pia, but did not penetrate it, provided good distri-
bution. Dr. Sampson said that it appears that the pia is
a significant barrier and that optimal distribution may
be obtained by placing the catheter tip close to the pia
without penetrating it.
Unlike the pia, the ependyma or resection cavities
provided no barrier to infused material. Imaging also
showed that when catheters crossed the deep sulci,
infused material tended to follow the pre-resection
catheter tract as if it were the path of least resis-
tance.
Experience with intra-tumoral infusions in this ser-
ies was limited but suggested that such infusions were
not particularly homogeneous. The material tended to
either pool in the necrotic center of the tumor or find a
pathway of least resistance through the enhancing
portion of the tumor while leaving the rest of the tumor
uncovered. It was initially hoped the natural egress of
fluid from the tumor would push the drug from the
tumor but that did not happen.
Dr. Sampson and his colleagues also evaluated CED
related changes in T2 signal. In 6 of 18 catheter
placements they found no change in T2 signals with
infusion. This allowed the identification of infusions
that failed to provide intraparenchymal drug distribu-
tion on SPECT. Five catheters placed into areas of low
pre-existing T2 signal showed signal changes during
infusion that were highly correlated with the volume
and geometry of 123I-HSA distribution. In seven cath-
eters placed in regions of pre-existing high T2 signal
abnormalities, T2 changes were noted but quantitative
correlations could not be established. One of the les-
sons of this study was that if there is no T2 signal
change after infusion, there is likely no infusion into
the brain.
Dr. Sampson discussed advances being made in
the software components of imaging systems, in
particular programs developed by BrainLAB and
Therataxis LLC for use with MRI and SPECT. The
program’s algorithm provides two useful pieces of
information. It will determine if a sulcus is present
and will offer predictions as to geometric volume
distribution. In recent trials, the sensitivity of the
sulcus detection component was 71% with a much
lower specificity. The average volume match was 60–
70%. The mean in-plane deviation was less than a
centimeter. The defined clinical utility of the pro-
gram was 86% allowing Dr. Samson to observe that
even with its current limitations, the system has
clinical utility.
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Dr. Sampson concluded his presentation with a
discussion of a study of immunological responses in the
presence of tumors. To answer the question as to
whether tumors were responding directly to the toxic-
ity of an agent or whether the agent was promoting a
secondary immunologic response against the tumor,
the investigators obtained mice with EGFRvIII over-
expressing GBM tumors and treated them with either a
toxin (MR1-1) specific to the EGF receptor or PBS.
The tumors injected with the toxin disappeared. Some
65 days after the treatment, the mice were again
challenged with EGFRvIII-positive tumors. The mice
appeared to be protected from this secondary tumor
challenge as there was no tumor take. Subsequent
investigation revealed that the efficacy of the toxin was
significantly reduced in the absence of CD4+ and
CD8+ T-cells and NK cells. Dr. Samson concluded that
although the work was preliminary, it appeared that
the toxins lose a significant amount of their efficacy in
the absence of an immune response.
In vivo imaging of CED
Russell R. Lonser, M.D. (National Institute of Neu-
rological Disorders and Stroke, National Institute of
Health) said that the ability to use imaging technol-
ogy to monitor infusions is one of the emerging
advantages of CED therapy. Dr. Lonser described his
work with two primary groups of surrogate tracers for
imaging, those that are used with MRI and those used
with computer tomography (CT). He observed that
one of the primary differences between MRI and CT
is that CT imaging can determine concentrations
based on Hounsfield units whereas the ability to use
signal on MRI to determine concentration is still
being investigated.
The first group of MR agents discussed were com-
pounds with high molecular weights. These were em-
ployed because their size approximated that of many of
the immunotoxins and other proteins being infused
into tumors [14]. One of these, a 76 kD gadolinium-
bound albumin molecule, was shown to provide clear
well-defined images in animals. Continuing study of the
compound shows that it has a high correlation of dis-
tribution with the therapeutic agent I125-labeled inter-
leukin 13 bound to Pseudomonas exotoxin (IL13-PE)
in rats and primates [15]. Autoradiograms of the gad-
olinium tracer superimposed on autoradiograms of
I125-IL13-PE treated brains revealed a 95% correlation
in volume.
Gadolinium-diethylenetriaminepentaacetic acid
(Gd-DTPA) is a readily available small molecule tra-
cer that produces clear images. The images produced
by Gd-DTPA correlated to within 13.5% of images
produced by tritiated gemcitabine. This 13.5% differ-
ence amounts to about a 0.6 mm difference in the
diameters of the images, a difference barely apparent
to the eye on MR imaging. He also noted that these
small molecule tracers were inaccurate at tracing larger
molecule therapeutic infusions.
Iopanoic acid covalently bound to albumin creates
a 70 kD molecule frequently used in CT imaging. It
provides a clear picture with good correlation of
intensity in Hounsfield units. Dr. Lonser described a
study which examined the safety and utility of an
iodine-based low-molecular weight surrogate tracers
for CT performed during CED in four primates [16].
The distribution of the tracer was determined by real-
time postinfusion CT as well as quantitative autora-
diography of small molecules (sucrose—MW 359 D)
or large molecules (dextran—MW 70 kD). The dis-
tribution of the infusate was identifiable for up to
72 h with no evidence of toxicity. The authors con-
cluded that real-time in vivo CT scanning of CED
iopamidol appeared to be safe, feasible and suitable
for monitoring CED delivery of drugs at low infusion
volumes.
Dr. Lonser presented a brief case study of a child
with Gaucher’s disease to illustrate how animal
studies translate to clinical applications. The study
was conducted to determine whether glucocerebrosi-
dase could be delivered successfully by CED and
reverse the child’s neurological decline. The child was
infused twice with a concentration of 1 mM of glu-
cocerebrosidase mixed with gadolinium DTPA. The
first infusion was in the frontal lobe but was con-
ducted without the tracer. The investigators found
that they were unable to track the infusate with either
T2 or FLAIR imaging. The right pontine region was
subsequently infused with glucocerebrosidase and
gadolinium DPTA through a silicate cannula. The
team was able to visualize the infusion in the right
posterior pontine region during 4 h of the 6 h proce-
dure. During this infusion, it became apparent that
some of the infusate was lost into the CSF space as a
pial barrier had been violated. Hence, the real-time
imaging provided valuable information about catheter
position and infusate flow.
Dr. Lonser concluded surrogate markers provide
well-defined images on either MRI or CT. Small mol-
ecule tracers have limitations in terms of their ability to
track the infusion of an infusate that contains macro-
molecules. Nevertheless, the tracers used to date
appear to be safe and they appear to have no affect on
the activity of therapeutic agents.
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Monitoring the effects of intratumoral paclitaxel
(Taxol) with MRI and FET-PET
There are an increasing number of models of drug
infusion, approaches to imaging the infusion and
approaches to imaging drug metabolism. Roland H.
Goldbrunner, M.D. (Department of Neurosurgery,
University of Munich, Germany) described a collabo-
rative phase I/II study of taxol infusion by CED in nine
patients with recurrent glioblastoma multiforme. He
noted that earlier studies of taxol in vitro showed that
it destroyed targeted cells but in vivo studies showed it
to have little to no efficacy owing to its inability to
cross the blood–brain barrier [17–23]. The trial he
described involved the implantation of two ventricular
catheters into the geometric center of the tumors as
determined by MRI and later by fluorodeoxyglucose-
positron emission tomography (FDG-PET). Dr.
Goldbrunner noted that FDG-PET data allowed better
catheter placement. He proposed that imaging with O-
(2-[18F]fluoroethyl)-L-tyrosine-PET (FET-PET) would
provide a better method to follow tumor growth than
with FDG-PET or MRI. Patients were infused with a
concentration of 0.25 mg/ml taxol at a rate of 1.8 mg/
day for five days. MRI and FET-PET was performed at
baseline. Diffusion-weighted MRI was performed
during convection on days 3 and 6. PET was performed
every 3 months there after.
All nine patients showed a response with a median
progression-free survival of 39 weeks and overall sur-
vival of 58 weeks. The one-year progression-free sur-
vival was 33.3% and one-year overall survival was
55.6%. The mean standardized uptake value (SUV) in
these patients was 3.2. After CED this was reduced by
17% to a value of 2.6 with the observation that the
SUV around the catheter tip was 2.0. When the tumors
recurred, there was a dramatic 46% increase in FET
uptake. In at least one patient the FET uptake was
larger than the area of MRI contrast enhancement. Dr.
Goldrunner summarized by saying that intratumoral
infusion of Taxol is effective but carries a significant
risk of side effects. There was good correlation
between images and FET uptake. It appears that FET-
PET is more sensitive than MRI in estimating tumor
extent and is significantly more specific in diagnosing
recurrences.
The value of intraoperative CT
Manfred Westphal, M.D. (University Hospital,
Eppendorf, Germany) described recent advances in
CT hardware and software, which may aid in catheter
placement. He said that frame-based CT offers optimal
control although the setup might be considered to be
laborious. The University Hospital in Eppendorf has a
dedicated CT that is linked to a mobile operating table.
The CT apparatus is mounted on fixed rails allowing it
to be moved when surgeons need access to the patient
and returned to its exact location for scanning. West-
phal described this prototype technology as being ext-
remely accurate, a quality that is a welcome virtue in
conducting CED procedures. The technology allowed
for extremely accurate placement of the catheters and
real-time verification of accurate placement.
Liposome-based CED therapeutics
Krys Bankiewicz, M.D., Ph.D. (Associate Professor of
Neurological Surgery, University of California, San
Francisco) described the potential of liposomes as
vehicles for delivering a wide variety of agents to target
regions and cells, calling them ‘‘universal delivery
vehicles.’’ The categories of agents liposomes can carry
include drugs, dyes, probes, imaging agents and genetic
material such as cDNA, siRNA, and viral vectors.
Monoclonal antibody structures can be incorporated
into liposomal membranes to allow the structure to
bind to specific cell receptors. The most frequently
used liposomes are around 100 nm but they can be as
small as 40 nm. Smaller liposomes limit the amount of
specific agents that can be carried to a target. The
structures are for the most part neutral in the biological
environment and although they are biodegradable,
they have a significant half-life. Pegylated liposomal
doxorubicin has a half-life of up to 50 h as compared to
10 min for the naked agent [24, 25]. Initially the cat-
ionic liposomes did not convect well, a problem that he
related to the cationic charge, but this problem was
overcome by peglyating [attaching polyethylene glycol
(PEG)] to the liposomes. Such peglyated structures are
sometimes called ‘stealth’ liposomes for their ability to
move in a biologic environment without engendering a
response. The peglyated liposomes are readily con-
vected and unlike other vectors they have the ability to
reach targeted tissue with close to 100% efficiency. Dr.
Bankiewicz showed photos of a liposomal-enclosed
marker reaching nearly every cell in the U87MG tumor
model. The liposome-delivered molecule did not dis-
criminate between neurons, astrocytes or tumor cells
said Dr. Bankiewicz. Another virtue liposomes possess
as vectors is that they also appear to diffuse well.
Dr. Bankiewicz turned the discussion to specific
agents, notably the topoisomerase inhibitor irinotecan
(CPT11) and doxorubicin. These drugs can be effi-
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ciently encapsulated in liposomes at high concentra-
tions, up to 105 molecules per liposome. Animal studies
show that when injected into peripheral circulation, the
free drug is cleared within 6 h but in liposomes it
remains stable for up to 48 h or longer and can be
detected for up to 50 days after a single injection.
Encapsulation also affects toxicity. A 20 mg/ml dose of
free drug convected into a rat brain is seen to be highly
toxic whereas liposomal doses of up to 80 mg/ml
evidence no toxicity.
Experiments with U87MG tumors in rats show sig-
nificantly increased survival. All animals receiving free
CPT11 at 3 mg/ml died within 35 days. More than half
the animals given liposomal CPT11 at 80 mg/ml
remained alive for more than 100 days. Similar
experiments with free topotecan versus liposomal
topotecan showed that animals receiving the free form
perished within 30 days following tumor implantation
where as more than 80% of those receiving the lipo-
somal form remained alive at 100 days. It was observed
by an audience member that although liposomes have
traditionally been considered to be fragile or unstable
structures that would be expected to breakdown under
the pressure of convection, the toxicology of free ver-
sus liposomal studies suggest this is not the case.
Responding to another query Dr. Bankiewicz said that
although CPT11 underwent decarboxylation to create
its active metabolite, SN38, the process may not be
necessary because robust destruction of cancer cells is
seen with the non-decarbolized agent suggesting that
CPT11 may be an active molecule in itself. He added
that a number of experiment show that CPT11 does
not undergo conversion to SN38 in tumors yet remains
active.
Spontaneous canine gliomas: a model system
for CED
Peter Dickinson, D.V.M. (University of California
Davis Veterinary Teaching Hospital) described the
potential that dogs with spontaneous brain tumors may
have for conducting investigations into optimizing
CED. Such tumors appear in dogs infrequently, but
more frequently than in humans, about 14.5 per
100,000 in the animals as compared to 4–9 per 100,000
in humans.
Distribution of histologies is slightly different in
canines than in humans but all types are seen. Tumor
histologies observed in dogs include astrocytomas, ol-
igodendrogliomas, ependymomas and choroid plexus
papillomas. About half of the canine tumors coming to
Dr. Dickinson’s clinic are meningiomas. Overall, only
about 20% of tumors are glioblastoma multiforme.
More commonly, grade 3 astrocytomas are observed.
The majority of gliomas appear in brachycelphalic
(squashed nosed) dogs such as boxers, bulldogs and
Boston terriers. About 90% of the oligodendrogliomas
present in Boxers.
The histologic features of canine brain tumors are
similar to those seen in humans. These tumors range
from grade 2 to grade 4 and include classic glioblas-
tomas containing serpentine necrosis, pseudopalisad-
ing, microvascular proliferation and other clinical
features. These tumors express many other molecular
alterations associated with human tumors to including
overexpression of VEGF, VEGFR-1, VEGFR-2,
EGFR1 PDGFRa, PDGF a/b, PPDGER b, and
IL13R2a. It has not yet been determined whether the
homologue to 1p/19q deletions is observed in canine
oligodendrogliomas.
Although all the cited factors seem to make dogs
ideal candidates as animals for CED trials, it is
important to recognize that these glioma-bearing dogs
are pets whose owners may have the same difficulty in
consenting to experimental procedures and treatments
as they would for other (human) family members.
Dr. Dickinson described the development of a
program to study tumors, therapies and technologies in
these animals and his group has developed an MR-
compatible frame for imaging and drug delivery. Dogs,
like primates, can be active so catheters must be well
anchored. The team at the hospital has had success
with UV curing dental acrylic, which is bound to brass
screws in the skull. He presented investigations with
CED infused liposomal CPT11/gadolinium. The cath-
eters were left in the dogs for three weeks before the
animals were euthanized. Histology showed very little
if any toxicity in the region of the liposomal infusion.
There was a very mild perivascular response that
appeared to involve macrophages. Dr. Dickinson
wondered aloud if the changes in post-infusion
enhancement seen in humans might be perivascular
reactions.
A case study was presented of a nine-year-old
spayed Jack Russell terrier diagnosed with a grade 3
astrocytoma. The readily observable glial filaments
were strongly GFAP-positive. CED was used to infuse
liposomal CPT11/Gd at a rate of about 3 ml/min. As in
some of the human studies presented in this sympo-
sium, the infused compound reached a finite volume of
distribution because the leading edge reached an
ependymal surface, the temporal horn of the animal’s
left ventricle. Leakage developed and the volume of
distribution became static despite continuing infusion
of drug.
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Dr. Dickinson concluded his presentation saying
that CED of CP11 is safe in dogs, placing infusions
directly into tumors via CED is a realistic goal, real-
time monitoring of the process allows rapid identifi-
cation of evolving problems, and that canine models
are likely to provide useful in vivo data for the devel-
opment of CED therapies.
CED of agents to treat medically intractable
epilepsy
John Heiss, MD, (National Institute of Neurological
Disorders and Stroke, National Institute of Health)
described investigations with CED in treating epilepsy.
The hippocampus is the primary site of surgically
remediable, medically intractable epilepsy and this
would be the presumed target of CED based therapies.
There are two approaches to treating epilepsy with
CED, neurophysiologic and pharmacologic. The for-
mer approach would involve delivering a selective
neurotoxin to destroy excitatory outflow from the
dentate gyrus of the hippocampus. The pharmacologic
approach would infuse a reversible inhibitory neuro-
transmitter into the ECS of the epileptic focus where it
can act on the post-synaptic membrane to suppress
hippocampal outflow.
The standard treatment of mesial temporal scle-
rosis, the most common epileptic syndrome in adults,
is to remove on the non-dominant side about 5 1/5 to
6 cm of the tip of the anterior temporal lobe. At one
year, 64% of the patients undergoing this procedure
are free of disabling seizures but only about 38%
were free of all seizures including auras [26]. Some
10–15% saw no improvement. He noted that in one
of the few controlled trials comparing surgery to
medical treatment, one of the patients in the medical
treatment arm died showing that epilepsy is not a
benign disease.
There is an effort by the National Institute of Neu-
rological Disorders and Stroke to develop CED as a
treatment approach reasoning that it may improve
outcomes and reduce side effects. Muscimol, a GABA-
A receptor agonist, was chosen because GABA is the
principle inhibitory neurotransmitter in mesial tempo-
ral sclerosis. Models show a loss of GABA-ergic neu-
rons in the granule layer of the hippocampus. Dr. Heiss
and his team chose to uses monkeys as a large animal
model for a preclinical study looking at safety and
distribution of muscimol delivered by CED.
The FDA required that the study design include a
treatment cross-over. Catheters were implanted in ten
animals with four of them acting as controls and
receiving no infusions. Three animals received musci-
mol and three received Elliot’s B solution as a vehicle.
Muscimol and the vehicle were infused at a rate of
84 ll/h for a little over 13 h. On day 11, the muscimol
animals were switched to Elliot’s B solution and those
receiving Elliot’s B were given Elliot’s B plus radio-
labled muscimol to allow for autoradiography at the
end of the experiment.
MRI and radiography showed the infused fluids
stayed within the hippocampus. Concentrations of
infusate ranged from 0.7% to 7% throughout the
targeted temporal lobe with no muscimol detected in
the contralateral temporal lobe.
At 24 h post infusion the fluid appeared to be
completely reabsorbed. Animals receiving muscimol at
14 lg/ml appeared normal. The muscimol reduced
EEG frequency. Those receiving the agent at 28.5 lg/
ml seemed to be calmed and those receiving 57 lg/ml
became lethargic. Histologic examination of the region
infused revealed some inflammatory cells around the
cannula site but the tissue otherwise appeared to be
completely normal. This study indicated that the infu-
sion of muscimol into the hippocampus by CED is both
feasible and safe. Further development of this anti-
seizure treatment approach is ongoing.
Ultrasound mediated interstitial drug delivery
Andrew Kanner, M.D. (Tel Aviv Sourasky Medical
Center, Israel) and his colleagues have been working
on a new delivery system that utilizes ultrasound as the
primary force driving drug dispersion from specially
designed catheters. The device consists of a primary
catheter inside a 1.2 mm diameter tube. The sound-
wave generated at the distal end of the device are
translated to a low amplitude mechanical force at the
tip of the device driving nano-particles through dis-
persion windows at the tip. A feeding system near the
proximal end of the catheter allows agents to enter the
system at an even flow.
The initial trials of the device were conducted in rats
with iron oxide nano-particles, which are 15–20 nm in
size when dry and 50–70 nm wet. The particles were
coated with dextran to simulate a drug-coated parti-
cles. One of the therapeutic approaches under con-
sideration is to deliver nano-particles coated with slow
release agents. The particles in a saline solution were
driven from the dispersal window at the distal end of
the catheter (the tip is sealed) by a 1–2 W power
source delivering a pulse duration between 1 s and 2 s
with amplitudes of 100–150 lm at the tip. Infusion
times ranged from 1 mm to 2 min, which produced a
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homogenous distribution of the particles covering most
of the frontal lobe of a rat.
A series of experiments with gadolinium DTPA, as
the agent, showed no significant dispersion. Dr. Kanner
explained that the gadolinium solution behaved like a
fluid whereas the nano-particles had completely
different properties and were not necessarily being
pushed through brain tissue like a fluid.
Histological examination of the tissue showed
localized trauma at the insertion site and along the
track of the probe but no signs of damage at the
periphery. Experiments in cow brains showed the
technology was able to disperse nano-particles over
distances up to 3 cm in as little as 2 min. The resonance
frequency of the brain tissue was found to be very
narrow and distribution halted when the frequency
drifted. A new probe was designed to have a feedback
mechanism that detects resonance drift and automati-
cally corrects for it. Initial pharmacological data
derived from particles coated with Adriamycin and
others coated with Taxol are being analyzed.
Responding to queries from the audience he said he
did not think the boundaries of cells and tissues would
be as great an issue with nano-particles as it appeared
to be with fluids in CED although that has yet to be
shown in tumor models. The particles his group have
used are small enough to pass through tissues. MRI
scans to date have shown no necrosis or edema in or
near the treatment area.
Clinical and basic advances in CED: Optimizing
convection for better clinical outcomes
Zvi Ram, M.D. (Tel Aviv Medical Center, Israel)
opened his remarks by identifying some of the chal-
lenges that needed to be overcome in order to optimize
the delivery agents that may someday produce better
clinical outcomes that current standards of therapy.
Anatomy plays a role in determining diffusion.
Diffusion tensor images can be fused with intraopera-
tive images and used as a tool to place catheters but
white matter, anatomic structures and barriers such as
scar tissue, gliosis, sulci and others can influence dif-
fusion patterns as was evidenced by the lengthy dis-
cussion of the problems of reflux or backflow that were
discussed early in the symposium. The toxicity of
agents is a two-pronged problem because it is difficult
at this point to control either the effect of the drugs
being used or their exact placement he said.
Imaging the convection offers a means of assessing
efficacy and safety. He described work being done by
Yael Mardor, Ph.D., of the Chiam Sheba Medical
Center, Tel Hashomer, Israel. Dr. Mardor has shown
that diffusion can be effectively imaged if gadolinium
diluted to a 1 in 70 concentration is added to the
infusate. Imaging response to treatment by a variety of
agents is possible with diffusion weighted MRI. The
agents include taxol and platinum-based compounds
whose response can be imaged within hours to immu-
nological agents whose response may not appear for
several days.
Choosing the appropriate drugs for CED can be
problematic. The requirements are that the drug under
consideration must be non-toxic to normal tissue and
stable in situ. Individual agents have individual char-
acteristics. Viscosity is a consideration. There is a lin-
ear correlation between viscosity, volume of
convection, and the incidence of backflow he said. The
size and molecular weight of drugs can affect convec-
tion and diffusion. He surmised that particles up to
100 nm can probably be convected. This is a size far
larger than thought possible only a few years ago. Dr.
Ram pointed out all CED work is progressing under
the assumption that better distribution is associated
with increased efficacy but that the hypothesis had yet
to be proven.
Dr. Ram advised the audience that CED is a
regional treatment and as such, it is limited in its scope
and goals. As his last clinical point, he noted that
intratumoral CED procedures may be significantly
different from peritumoral approaches. Each proce-
dure must be tailored according to the mode of con-
vection, the specific infusate being used, the flow rate,
the character of the catheters employed and the clinical
characteristics of the patient being treated.
Future directions
The pace of development of the field of CED
depends heavily on the outcome of the first phase III
trial to complete patient accrual (NeoPharm Inc.’s
PRECISE trial). This trial, which was closed in
December, 2005, randomized patients, with recurrent
GBM treated with a gross-total resection of the
recurrent enhancing disease, to treatment with cin-
tredekin besudotox (CB) via CED or with Gliadel
chemotherapy wafers implanted at the time of sur-
gery. The results of this trial are expected to be
available in early 2007. If this trial shows a sufficient
survival benefit following treatment with CB, it is
expected that further development of this drug (and
other related drugs) will proceed at an accelerated
pace. On the other hand, failure of this trial to show
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benefit of the experimental regimen will likely result
in a much slower pace of progress due to the signifi-
cant cost of clinical trials that involve the implanta-
tion of intracerebral catheters for CED. In that case,
further clinical advances would be more likely to arise
from small, single center trials or from non-glioma
applications of CED. The Third International Sym-
posium on Convection Enhanced Delivery will be
held in Cleveland in May, 2007, at which time the
results of this trial and other updates from the field of
CED will be presented and discussed.
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